tailieunhanh - Báo cáo y học: "DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis. | Available online http content 7 5 189 Commentary DAS28 a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis Piet LCM van Riel and Jaap Fransen Department of Rheumatology Radboud University Nijmegen Medical Centre Nijmegen The Netherlands Corresponding author Piet LCM van Riel Published 22 August 2005 Arthritis Research Therapy 2005 7 189-190 DOI ar1820 This article is online at http content 7 5 189 2005 BioMed Central Ltd See related research by Vander Cruyssen et al. in this issue http content 7 5 R1063 Abstract The Disease Activity Score using 28 joint counts DAS28 has been developed in a cohort of patients with rheumatoid arthritis in which only conventional anti-rheumatic treatments were used. It has extensively been validated to monitor disease activity in daily clinical practice as well as in clinical trials. The study of Vander Cruyssen and colleagues showed that the DAS28 correlated best with the decisions of rheumatologists to increase the infliximab dose because of insufficient response. This result once more confirms the validity of the DAS28 to monitor disease activity in patients with rheumatoid arthritis and to titrate treatment with biologicals. In daily clinical practice the Disease Activity Score using 28 joint counts DAS28 is used to monitor the disease activity of rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs DMARDs and biological agents. This is useful to inform the rheumatologist about whether the treatment is producing the expected effects in an appropriate period of time or whether the treatment should be more intensified. In an article in the present issue Vander Cruyssen and colleagues investigated which variables can best be measured to evaluate the effect of therapy and the remaining disease activity in daily clinical practice 1 . This study was based on a cohort of .